A revolutionary new delivery platform
Introducing the Fusogenix PLV
Recent advances in the development of high precision genetic therapies have put cures within reach for previously untreatable diseases and conditions. Therapies in development have the potential to eradicate genetic diseases, block cancer, and reverse aging.
The Fusogenix PLV delivery platform is formulated with our proprietary fusogenic FAST proteins to drive fusion and intracellular delivery of therapeutic nucleic acid payloads to cells and tissues throughout the body - to make these much needed therapies a reality.
Powered by fusion, naturally
FAST proteins are the smallest fusogens in nature
Our PLV technology is a fusion-powered delivery system for RNA and DNA
Our PLV technology is a fusion-powered delivery system for RNA and DNA
Fusion Associated Small Transmembrane (FAST) proteins catalyze the mixing of lipids between nanoparticles and the plasma membrane of target cells.
Our PLV technology is a fusion-powered delivery system for RNA and DNA
Our PLV technology is a fusion-powered delivery system for RNA and DNA
Our PLV technology is a fusion-powered delivery system for RNA and DNA
In our PLV platform, FAST proteins mediate direct fusion with the cell membrane, bypassing endocytosis and delivering RNA, DNA or gene editing therapies directly into the cytoplasm of the cell.
A completely new mechanism of delivery
The Fusogenix PLV platform is a fusion-powered delivery system for genetic medicines that combines the best aspects of viral and non-viral approaches. Using a completely new mechanism for intracellular delivery of RNA, DNA and gene editing therapies, the Fusogenix PLV is suitable for a wide range of best-in-class genetic medicines.
A platform with no limitations
Broad yet precise biodistribution
The Fusogenix PLV technology is inherently non-liver tropic, enabling the delivery of therapeutic doses of nucleic acid therapies to cells and tissues throughout the body.
Suitable for repeat dosing
The PLV platform is non-immunogenic, which allows for repeat dosing of genetic medicines.
Fusogenix AIM Precision Targeting
Fusogenix Advanced Interactive Modules (AIM) technology allows for precision targeting of cell and tissues throughout the body. Our AIM platform leverages high selectivity ligands incorporated into the FAST protein to display molecular targeting modules on the outer surface of the Fusogenix PLV.
FOCUS-AI Formulation Design
Our Fusogenix Optimization and CUStomization with AI (FOCUS-AI) workflow leverages the unique features of our Fusogenix PLV platform to design bespoke delivery solutions for cell and tissue targeting.
The novel fusion mechanism of PLV delivery provides an unprecedented and vast formulation design space to incorporate known and novel lipids. Our purpose-built AI algorithms draw upon years of iterative training data to create novel PLV formulations with unique features.
Our development programs are built upon FOCUS-AI optimized PLV formulations for vaccines, gene therapy, ocular and lung diseases.
Fusogenix Systemic PLV
Fusogenix Systemic PLV
Fusogenix Systemic PLV
This PLV has been developed to enable systemic gene therapies and gene editing approaches using RNA or DNA. This formulation is the basis for our obesity and rare metabolic disease programs.
Fusogenix Ocular PLV
Fusogenix Systemic PLV
Fusogenix Systemic PLV
This PLV has been developed to enable gene editing and gene therapy approaches in the eye through multiple routes of administration. This formulation is the basis for our Stargardt disease program.
Fusogenix Lung PLV
Fusogenix Vaccine PLV
Fusogenix Vaccine PLV
This PLV has been developed to enable gene editing and gene therapy approaches to the lung after systemic administration.
Fusogenix Vaccine PLV
Fusogenix Vaccine PLV
Fusogenix Vaccine PLV
This PLV has been developed to enable a potent and durable immune response to one or more antigens after intramuscular administration. This formulation is the basis for our COVID-19 booster clinical program.